Oxycodone and Lorbrena drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Oxycodone and Lorbrena. Common interactions include death among females and contusion among males.

The phase IV clinical study analyzes what interactions people who take Oxycodone and Lorbrena have. It is created by eHealthMe based on reports of 11 people who take Oxycodone and Lorbrena from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.



On Jun, 30, 2022

11 people who take Oxycodone and Lorbrena together, and have interactions are studied.


What is Oxycodone?

Oxycodone has active ingredients of oxycodone hydrochloride. It is often used in pain. eHealthMe is studying from 101,841 Oxycodone users for its effectiveness, alternative drugs and more.

What is Lorbrena?

Lorbrena has active ingredients of lorlatinib. eHealthMe is studying from 889 Lorbrena users for its effectiveness, alternative drugs and more.

Number of Oxycodone and Lorbrena reports submitted per year:

Oxycodone and Lorbrena drug interactions.

Common Oxycodone and Lorbrena drug interactions by gender *:

female:

  1. Death
  2. Decreased appetite
  3. Disseminated intravascular coagulation
  4. Hyperkalaemia
  5. Sleep disorder
  6. Blood cholesterol increased

male:

  1. Contusion
  2. Death
  3. Peripheral swelling
  4. Anxiety
  5. Delirium
  6. Hyperthermia
  7. Neoplasm progression
  8. Dysphonia
  9. Oedema

Common Oxycodone and Lorbrena drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Blood cholesterol increased
  2. Decreased appetite
  3. Sleep disorder

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Death
  2. Oedema

60+:

  1. Contusion
  2. Peripheral swelling
  3. Anxiety
  4. Delirium
  5. Hyperthermia
  6. Neoplasm progression
  7. Death
  8. Disseminated intravascular coagulation
  9. Dysphonia
  10. Hyperkalaemia

Common conditions people have *:

  1. Lung Neoplasm Malignant (cancer tumour of lung): 6 people, 54.55%
  2. Lung Carcinoma Cell Type Unspecified Stage 0 (the lung cancer has not spread beyond the inner lining of the lung): 2 people, 18.18%
  3. Neoplasm Malignant (cancer tumour): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Oxycodone and Lorbrena?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Oxycodone and Lorbrena:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Oxycodone interactions:

Browse all interactions between Oxycodone and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on oxycodone hydrochloride and lorlatinib (the active ingredients of Oxycodone and Lorbrena, respectively), and Oxycodone and Lorbrena (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: